Analyst Review Alert: Insmed Incorporated (NASDAQ:INSM)

Analysts are weighing in on how Insmed Incorporated (NASDAQ:INSM) , might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.8. The stock is rated as buy by 4 analysts, with 2 outperform and 1 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 6.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.56 a share, which would compare with $-0.47 in the same quarter last year. They have a high estimate of $-0.52 and a low estimate of $-0.60.

For the full year, 6.00 Wall Street analysts forecast this company would deliver earnings of -2.24 per share, with a high estimate of $-1.89 and a low estimate of $-2.42. It had reported earnings per share of $-2.02 in the corresponding quarter of the previous year.

Among the 7 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for INSM is $22.71 but some analysts are projecting the price to go as high as $35.00. If the optimistic analysts are correct, that represents a 218 percent upside potential from the recent closing price of $11.02. Some sell-side analysts, particularly the bearish ones, have called for $13.00 price targets on shares of Insmed Incorporated (NASDAQ:INSM) .

In the last reported results, the company reported earnings of $-0.47 per share, while analysts were calling for share earnings of $-0.48. It was an earnings surprise of 2.10%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapies for patients with serious lung diseases. The companys lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for patients with nontuberculous mycobacteria lung disease. It is also developing INS1009, a nebulized treprostinil prodrug that is in Phase I study for pulmonary arterial hypertension, idiopathic pulmonary fibrosis, sarcoidosis, and severe refractory asthma. Insmed Incorporated was founded in 1999 and is headquartered in Bridgewater, New Jersey.